Clinical trial · Interventional
Analysis of Circulating Tumor Markers in the Blood (ALCINA)
Analysis of Circulating Tumor Markers in the Blood
NCT02866149CI-TRIAL-00081160ALCINAcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Exploratory study on blood-borne biological markers and their correlation with clinical and pathological characteristics.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sampling | Biological | — | UNRESOLVED |
| Stool sampling | Other | — | UNRESOLVED |
| Tumor sampling | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (16)
- type
- OTHER
- label
- Cohort 1 - "Anti checkpoint"
- description
- Monitoring of patients with tumours treated by immune therapy. Timing of blood sampling: * inclusion * after #8 weeks on therapy * at progression or 6 months from inclusion for patient without progressive disease * if toxicity grade 3 or 4, or grade 2 until 1 month.
- interventionNames
- Biological: Blood sampling
- type
- OTHER
- label
- Cohort 2 - "Oncoscan®"
- description
- Monitoring of patients with HER 2+/- breast cancer and correlation with genome-wide copy number, loss of heterozygosity detection, as well as identification of frequently tested somatic mutations (Oncoscan® assays). Timing of blood sampling: * inclusion * after 1 cycle of therapy (weeks 3-4) * up to 2 other samples, timepoints decided by the investigator
- interventionNames
- Biological: Blood sampling
- type
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient with any tumoral disease (proven or suspected), of any type and stage 2. More than18 years old 3. Signed informed consent form Additional inclusion criteria if a tumor sample is needed: 4. Tumor considered as accessible by biopsy 5. Normal blood coagulation tests on the last blood analysis Non-inclusion Criteria: 1. Patient in detention or protected by the law 2. Patient who cannot comply with the study follow up for geographical, social or psychological reasons Additional non-inclusion criteria if a tumor sample is needed: 3. Anticoagulant or antiaggregant that cannot be interrupted for the biopsy 4. central-nervous system metastases only (unless a diagnostic or curative surgery is planned before the inclusion in the study)
References
Publications (7)
- DERIVEDRampanou A, Rodrigues M, Bidard FC, Cassoux N, Matet A, Vincent-Salomon A, Jeannot E, Bieche I, Roman-Roman S, Stern MH, Renault S. Circulating Tumor DNA Monitoring in Patients with Uveal Melanoma Using Mutation-Agnostic Multiplex Drop-Off ddPCR Assays. Anal Chem. 2026 May 19;98(19):14260-14269. doi: 10.1021/acs.analchem.6c00476. Epub 2026 May 4. PMID 42082165
- DERIVEDRodrigues M, Ramtohul T, Rampanou A, Sandoval JL, Houy A, Servois V, Mailly-Giacchetti L, Pierron G, Vincent-Salomon A, Cassoux N, Mariani P, Dutriaux C, Pracht M, Ryckewaert T, Kurtz JE, Roman-Roman S, Piperno-Neumann S, Bidard FC, Stern MH, Renault S. Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp. Nat Commun. 2024 Oct 14;15(1):8851. doi: 10.1038/s41467-024-53145-0. PMID 39402032
- DERIVEDEslami-S Z, Cortes-Hernandez LE, Sinoquet L, Gauthier L, Vautrot V, Cayrefourcq L, Avoscan L, Jacot W, Pouderoux S, Viala M, Thomas QD, Lamy PJ, Quantin X, Gobbo J, Alix-Panabieres C. Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer. Br J Cancer. 2024 Jan;130(1):63-72. doi: 10.1038/s41416-023-02491-9. Epub 2023 Nov 16. PMID 37973956
- DERIVEDSinoquet L, Jacot W, Gauthier L, Pouderoux S, Viala M, Cayrefourcq L, Quantin X, Alix-Panabieres C. Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer. Clin Chem. 2021 Nov 1;67(11):1503-1512. doi: 10.1093/clinchem/hvab131. PMID 34355741
- DERIVEDDarrigues L, Pierga JY, Bernard-Tessier A, Bieche I, Silveira AB, Michel M, Loirat D, Cottu P, Cabel L, Dubot C, Geiss R, Ricci F, Vincent-Salomon A, Proudhon C, Bidard FC. Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients. Breast Cancer Res. 2021 Mar 6;23(1):31. doi: 10.1186/s13058-021-01411-0. PMID 33676547